These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2453339)

  • 21. Effect of (Des-Tyr)-gamma-endorphin in schizophrenia.
    Meltzer HY; Busch DA; Tricou BJ; Robertson A
    Psychiatry Res; 1982 Jun; 6(3):313-26. PubMed ID: 6125982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Animal and clinical research on neuropeptides and schizophrenia.
    van Ree JM; Verhoeven WM; de Wied D
    Prog Brain Res; 1987; 72():249-67. PubMed ID: 2441432
    [No Abstract]   [Full Text] [Related]  

  • 23. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance.
    Singh MM
    Dis Nerv Syst; 1976 Apr; 37(4):191-6. PubMed ID: 767080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Principles of chemotherapy of paranoid schizophrenia].
    Vanelle JM; Loloum T
    Encephale; 1991; 17(4):235-40. PubMed ID: 1683623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is cholecystokinin therapeutic in chronic schizophrenia?
    Boza RA; Rotondo DJ
    J Clin Psychiatry; 1985 Nov; 46(11):485-6. PubMed ID: 3902807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hla, and the response to treatment with gamma-type endorphins in schizophrenia.
    de Jongh BM; Verhoeven WM; van Ree JM; de Wied D; van Rood JJ
    J Immunogenet; 1982 Dec; 9(6):381-8. PubMed ID: 6186747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic properties of Des-enkephalin-gamma-endorphin in treatment of schizophrenic patients.
    Verhoeven WM; van Ree JM; Heezius-van Bentum A; de Wied D; van Praag HM
    Arch Gen Psychiatry; 1982 Jun; 39(6):648-54. PubMed ID: 7092498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic effect of gamma-type endorphins in schizophrenia.
    van Ree JM; de Wied D; Verhoeven WM; van Praag HM
    Lancet; 1980 Dec 20-27; 2(8208-8209):1363-4. PubMed ID: 6109172
    [No Abstract]   [Full Text] [Related]  

  • 29. [Beta-endorphin concentration in the cerebrospinal fluid of schizophrenics].
    Ignatov SA; Burbaeva GSh; Tsutsul'kovskaia MIa; Abramova LI; Trubnikov VI
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(9):1331-7. PubMed ID: 6108032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs.
    Emrich HM; Höllt V; Bergmann M; Kissling W; Schmid W; Zerssen DV; Herz A
    Adv Biochem Psychopharmacol; 1980; 22():489-502. PubMed ID: 6104902
    [No Abstract]   [Full Text] [Related]  

  • 31. (Des-Tyr)gamma-endorphin for schizophrenia. A critical review.
    Manchanda R; Hirsch SR
    Int Pharmacopsychiatry; 1982; 17(3):147-52. PubMed ID: 6128328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptic medication: the literature and implications for mental health nursing.
    Usher K; Happell B
    Aust N Z J Ment Health Nurs; 1996 Dec; 5(4):191-8. PubMed ID: 9079316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contingent negative variation and schizophrenia: a long-term follow-up study.
    Rizzo PA; Spadaro M; Albani GF; Morocutti C
    Biol Psychiatry; 1984 Dec; 19(12):1719-24. PubMed ID: 6151404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report.
    Tamminga CA; Tighe PJ; Chase TN; DeFraites EG; Schaffer MH
    Arch Gen Psychiatry; 1981 Feb; 38(2):167-8. PubMed ID: 7212942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of the synthetic peptides gamma-type endorphins in mentally ill patients.
    van Ree JM; Verhoeven WM; de Wied D; van Praag HM
    Ann N Y Acad Sci; 1982; 398():478-95. PubMed ID: 6186176
    [No Abstract]   [Full Text] [Related]  

  • 36. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
    Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
    Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conditioning in the prediction of drug withdrawal effects in chronic schizophrenic patients.
    Ban TA; Ananth JV; Lehmann HE
    Act Nerv Super (Praha); 1974 Mar; 16(1):23-33. PubMed ID: 4156144
    [No Abstract]   [Full Text] [Related]  

  • 38. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.
    Mishara AL; Goldberg TE
    Biol Psychiatry; 2004 May; 55(10):1013-22. PubMed ID: 15121486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An open study with a new long-acting neuroleptic.
    Fleischhauer J; Angst J; Padrutt A; Vetter P
    Act Nerv Super (Praha); 1973 May; 15(2):85-6. PubMed ID: 4752678
    [No Abstract]   [Full Text] [Related]  

  • 40. [Indications for long-term neuroleptic medication--standard procedure or individual prognosis-guided intervention? A prospective study of the clinical treatment model].
    Gaebel W; Pietzcker A
    Nervenarzt; 1983 Sep; 54(9):467-76. PubMed ID: 6138719
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.